PALO ALTO, Calif., April 6 /PRNewswire/ -- Affymax, Inc., a clinical-stage pharmaceutical company, today announced that Paul B. Cleveland, chief financial officer and executive vice president of corporate development, will present at the BIO 2006 Business Forum on Tuesday, April 11, at 10:30 a.m. CDT during the BIO 2006 Annual International Convention at the McCormick Place Convention Center in Chicago.
Mr. Cleveland will provide an update on the clinical development program for Hematide(TM), a synthetic, peptide-based, next-generation erythropoiesis-stimulating agent (ESA). Hematide is designed to stimulate the production of red blood cells and is being evaluated in Phase 2 clinical trials to treat anemia in patients with chronic kidney disease (CKD) and cancer. Affymax recently announced a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Hematide in Japan.
About Affymax
Affymax, Inc. is a clinical-stage pharmaceutical company that is developing a rich pipeline of synthetic peptide-based drugs against clinically validated targets for the treatment of kidney diseases and cancer. Hematide(TM), the Company's first product candidate to enter the clinic, is a novel peptide-based drug designed to stimulate the production of red blood cells. Currently, it is in Phase 2 trials for the treatment of anemia associated with chronic kidney disease and cancer. For more information go to www.affymax.com.
Affymax, Inc.CONTACT: Mary Fermi, Senior Director, Commercial Development of Affymax,Inc. +1-650-812-8722; or media, Daryl Messinger of WeissComm Partners,Inc., +1-415-999-2361, or daryl@weisscommpartners.com
Web site: http://www.affymax.com/
